<DOC>
	<DOCNO>NCT01599377</DOCNO>
	<brief_summary>The overall aim study establish bioequivalence commercial tofacitinib tablet formulation tofacitinib capsule formulation .</brief_summary>
	<brief_title>Tofacitinib Bioequivalence Study Comparing Tablets And Capsules</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female ( nonchildbearing potential ) subject age 21 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include oral temperature , BP PR measurement , 12 Lead ECG clinical laboratory test . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>